Neogenomics (NEO) Other Non-Current Liabilities (2017 - 2026)

Neogenomics has reported Other Non-Current Liabilities for 10 years, with the latest figure at $12.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 0.91% year-over-year to $12.0 million; the trailing twelve-month figure through Mar 2026 stood at $12.0 million (up 0.91% YoY), and the FY2025 full-year result was $12.1 million, up 2.52% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $12.0 million, roughly flat from $12.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $14.2 million in Q3 2022, with the low at $11.5 million in Q2 2024.
• Historically, Other Non-Current Liabilities has averaged $12.7 million across 5 years, with a median of $13.0 million in 2024.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 281.47% — and 2024, when it dropped 11.4%.
• Neogenomics' Other Non-Current Liabilities stood at $13.1 million in 2022, then decreased by 0.16% to $13.0 million in 2023, then declined by 9.68% to $11.8 million in 2024, then rose by 2.52% to $12.1 million in 2025, then slipped by 0.32% to $12.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $12.0 million (Q1 2026), $12.1 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.